GlassScriptPhysician profile
Taylor Peabody
NPI 1548721061
$47,610.18
in general payments reported to CMS, 2019-2025
13 companies · $500 in 2025
The $500 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $20K · 2024: $27K · 2025: $500.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $44K · Travel and Lodging: $2,318 · Food and Beverage: $1,201.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $44,091.00 |
| Travel and Lodging | $2,317.81 |
| Food and Beverage | $1,201.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $21,364.55 | 2023-2024 | Activa PC, Percept PC Brainsense |
| Boston Scientific Corporation | $15,091.68 | 2024-2025 | Vercise, General - Dbs |
| Abbott Laboratories | $10,476.31 | 2024 | Infinity, Proclaim |
| Amneal Pharmaceuticals LLC | $256.84 | 2023-2025 | Crexont, Rytary |
| Abbvie INC. | $139.08 | 2023-2025 | |
| Ucb, INC. | $99.53 | 2025 | |
| Kyowa Kirin, INC. | $45.82 | 2024 | Nourianz |
| Teva Pharmaceuticals USA, INC. | $30.34 | 2025 | Austedo Xr |
| Merz Pharmaceuticals, LLC | $27.48 | 2025 | Xeomin, Inbrija |
| Ge Healthcare | $20.48 | 2025 | |
| Acadia Pharmaceuticals INC | $19.96 | 2025 | Nuplazid |
| Neurocrine Biosciences, INC. | $19.42 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $18.69 | 2025 | Dysport |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Peabody listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.